These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11097344)

  • 1. Cancer therapy and polymorphisms of cytochromes P450.
    MacLeod SL; Nowell S; Massengill J; Jazieh A; McClure G; Plaxco J; Kadlubar FF; Lan NP
    Clin Chem Lab Med; 2000 Sep; 38(9):883-7. PubMed ID: 11097344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer pharmacogenomics: achievements in basic research.
    Nakajima M; Yokoi T
    Int J Clin Oncol; 2005 Feb; 10(1):14-9. PubMed ID: 15729595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP450 pharmacogenetics for personalizing cancer therapy.
    van Schaik RH
    Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs.
    Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
    Acta Pol Pharm; 2008; 65(3):307-18. PubMed ID: 18646550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
    Rochat B
    Clin Pharmacokinet; 2005; 44(4):349-66. PubMed ID: 15828850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
    Mathijssen RH; van Schaik RH
    Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
    Manikandan P; Nagini S
    Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
    Zanger UM; Schwab M
    Pharmacol Ther; 2013 Apr; 138(1):103-41. PubMed ID: 23333322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.
    Venkatakrishnan K; Von Moltke LL; Greenblatt DJ
    J Clin Pharmacol; 2001 Nov; 41(11):1149-79. PubMed ID: 11697750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 and anticancer drugs.
    Fujita K
    Curr Drug Metab; 2006 Jan; 7(1):23-37. PubMed ID: 16454691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
    Lee IS; Kim D
    Arch Pharm Res; 2011 Nov; 34(11):1799-816. PubMed ID: 22139682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of cytochrome P450 enzymes in the metabolism of antineoplastic drugs].
    Quiñones S L; Rosero P M; Roco A A; Moreno T I; Sasso A J; Varela F N; Cáceres L D; Saavedra S I
    Rev Med Chil; 2008 Oct; 136(10):1327-35. PubMed ID: 19194632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytochromes P450: xenobiotic metabolism, regulation and clinical importance].
    Guéguen Y; Mouzat K; Ferrari L; Tissandie E; Lobaccaro JM; Batt AM; Paquet F; Voisin P; Aigueperse J; Gourmelon P; Souidi M
    Ann Biol Clin (Paris); 2006; 64(6):535-48. PubMed ID: 17162257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the world of cytochrome P450 enzymes.
    Frye RF
    Mol Interv; 2004 Jun; 4(3):157-62. PubMed ID: 15210869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.